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Abstract
Background: Prevalence estimates for celiac disease (CD) depend on the method used. The role of deamidated gliadin
peptide (DGP) and genetic testing in epidemiological studies and diagnostic settings of celiac disease (CD) has still to be
established.
Objectives: The objective of this article is to assess the prevalence of CD in Latvia by combining serological tests with DQ2.5/
DQ8 testing.
Methods: A total of 1444 adults from a randomly selected cross-sectional general population sample were tested by ELISA
for tTG IgA, DGP IgA and IgG antibodies (QUANTA Lite, Inova Diagnostics Inc). Samples with tTG IgA 20U were tested for
EMA IgA by indirect immunofluorescence assay, and all specimens with tTG IgA 15U were tested by QUANTA-Flash
chemiluminescent assays (CIA) (Inova Diagnostics Inc) for tTG IgA, DGP IgA and IgG. DQ2.5/8 was detected in individuals
with any positive ELISA test and a subgroup of controls.
Results: Forty-three individuals (2.98%; 95% CI: 2.10–3.86%) tested positive by at least one ELISA test; 41.86% of the
serology-positive individuals (any test above the cutoff) were DQ positive. Six individuals (0.42%; 95% CI: 0.09–0.75%) were
triple ELISA positive, and DQ2.5 or DQ8 was positive in all; 0.35% (95% CI: 0.05–0.65%) were tTG IgA and EMA positive. Two
tTG IgA-negative cases were both DGP IgG and IgA positive, both being DQ positive; including them in the ‘‘serology-
positive’’ group would increase the prevalence to 0.49% (95% CI: 0.13–0.85%).
CIA tests revealed 2 tTG IgA-positive and EMA-negative cases with a positive genotype. DQ2.5 or DQ8 genotype was positive
in 28.6% of the serology-negative population.
Conclusions: Estimates of the prevalence of CD in Latvia based on the serogenetic testing approach range from 0.35% to
0.49% depending on the criteria used. There is a rationale for combining serological tests and DQ2.5/8 genotyping.
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Introduction
The prevalence of celiac disease in Europe and North
America is generally considered approximately 0.7%–
1.5%, although ﬁve- to eight-fold inter-country vari-
ations have been observed among Northern, Western
and Southern European countries.1–3 Countries with
the highest prevalence include Finland,2,4–6 Sweden7,8
1University of Latvia, Faculty of Medicine, Riga East University Hospital,
Riga, Latvia
2Inova Diagnostics Inc, San Diego, CA, USA
3Latvian Biomedical Research and Study Centre, Riga, Latvia
4University of Latvia, Riga, Latvia
5Institute of Cardiology, University of Latvia, Riga, Latvia
6University of Latvia, Faculty of Medicine, Pauls Stradins Clinical University
Hospital, Riga, Latvia
Corresponding author:
Marcis Leja, Riga East Clinical University Hospital, University of Latvia, 6
Linezera iela, LV1006 Riga, Latvia.
Email: cei@latnet.lv
United European Gastroenterology Journal
2015, Vol. 3(2) 190–199
! Author(s) 2015
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2050640615569379
ueg.sagepub.com
(both countries located near Latvia), and
Great Britain.2,9
The prevalence of celiac disease has grown in parallel
with autoimmune and allergic disease; e.g. simultan-
eous growth of celiac disease and diabetes mellitus
type 1 has been well demonstrated.4 The epidemiology
of non-infectious diseases varies considerably among
diﬀerent areas in Europe. Our previous data obtained
from the International Study for Asthma and Allergies
in Childhood (ISAAC) demonstrated signiﬁcantly
lower prevalence of asthma, allergic rhinoconjunctivitis
and atopic eczema symptoms in Latvia (and other
countries in Eastern Europe) compared to Nordic
countries.10 It is possible similar diﬀerences may
also be seen in the prevalence of celiac disease.
Kondrashova et al. compared two populations sharing
a similar genotypic background but living under diﬀer-
ent socioeconomic and hygienic conditions in the bor-
dering areas of Finland and Russian Karelia.11 They
concluded celiac disease was signiﬁcantly more preva-
lent in areas with better socioeconomic conditions and
hygiene.
Currently the standard initial evaluation of patients
with suspected celiac disease includes testing for
immunoglobulin (Ig)A antibodies to tissue transgluta-
minase (tTG IgA).12–14 Recently the use of deamidated
gliadin peptide (DGP) tests has emerged.15,16 DGP (in
particular, the DGP IgG test) may identify celiac dis-
ease patients by negative tTG IgA and anti-endomysial
IgA (EMA) tests,17 especially IgA-deﬁcient individuals.
Almost all individuals with celiac disease are positive
for human leukocyte antigen (HLA)-DQ2.5 or DQ8
genes. While absence of these genes makes the presence
of celiac disease extremely unlikely in most populations
and thus a strong negative predictor of disease, these
genes are present in a considerable proportion of the
general population and are only of value to indicate the
unlikely presence of celiac disease in those without this
genetic background. In Western Europe, the allele fre-
quency of DQ2 ranges from 5% to 20%, while that of
DQ8 ranges from 5% to 10%.1
Algorithms guiding the routine clinical use of celiac
disease-related serological and genetic assays are still
evolving. Recent guidelines of the European Society
of Paediatric Gastroenterology and Nutrition
(ESPGAN)18 allow consideration of omitting duodenal
biopsies for diagnosing celiac disease in children based
on transglutaminase, EMA and DQ2/DQ8 test results
on particular occasions. Duodenal biopsy is generally
required for diagnosing the disease in adults although
several studies have suggested adequate accuracy for
serology alone along the lines of the ESPGAN guide-
lines, taking into account cutoﬀ levels for positivity
may also be useful for adult patients.19–22 It should be
noted that the prevalence estimates of celiac disease are
substantially inﬂuenced by the method used in the
assessment, i.e. whether seroprevalence only is con-
sidered, or biopsy conﬁrmation of the disease is
required.23
Currently, the clinical value of adding the HLA
DQ2/DQ8 test to serology in diagnosing celiac disease
in adults is not well deﬁned.24 The combination of ser-
ology with HLA DQ testing has been suggested by a
few authors to help guide selection of patients for
endoscopy and small-bowel biopsy.25,26 However,
Hadithi et al.24 have found that the combination of
serological and HLA DQ testing is as accurate as
either of these strategies alone, and have concluded
that for diagnostic purposes these non-invasive strate-
gies cannot substitute for small-bowel biopsy. Recently,
a serogenetic approach was proposed by Anderson
et al.27 for determining the community prevalence of
celiac disease.
Limited information is available on the prevalence of
celiac disease in Eastern Europe. The objective of our
study was to assess the prevalence of celiac disease in
Latvia based on serology testing alone or in combin-
ation with genetic testing. We did not pre-deﬁne the
criteria for seropositivity since several serological as
well HLA DQ2/DQ8 testing methods were used. We
employed conventional tTG IgA and DGP enzyme-
linked immunosorbent assays (ELISAs) as well as
new chemiluminescent-based versions of these immuno-
assays (CIA). Finally we tested all specimens with posi-
tive results by any assay (tTG IgA, DGP IgG, or DGP
IgA) for the presence of HLA DQ2.5/DQ8 genotypes to
further clarify the serology results obtained on the
study population. Using this methodology, we aimed
to investigate the diﬀerences in the prevalence results
of celiac disease under circumstances when diﬀerent
non-invasive diagnostic approaches are employed.
Methods
Study group selection
The study was performed as a sub-analysis of a larger
randomly selected cross-sectional sample of an adult
general population aged 24–74, the methodology of
which has been described elsewhere.28 With the primary
objective of exploring cardiovascular risk factors, a
total of 6000 invitees equally spilt between age groups
and genders were randomly selected from the National
Latvian population registry covering the entire country
in 2008–2009; of these, 3807 accepted the invitation and
participated in the study. In exceptional cases, adult
members of the family or partners were also included,
but not actively invited; a minor proportion of them
were outside the invitation group age range. A sub-
group of these individuals for whom serum samples
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were available was included in our study. Serum sam-
ples received from the clinical laboratory following rou-
tine clinical testing were stored at 70C until
additional testing was conducted. DNA samples were
provided by the Latvia Genome Data Base group.
All specimens with positive results for any assay
were referred for genetic testing. In addition, at least
six matched control cases to every serology-positive
individual from the serology-negative group were gen-
otyped to evaluate the DQ positivity in the serology-
negative group.
Serology
All samples were blinded and tested by ELISA for tTG
IgA (QUANTA Lite h-tTG IgA ELISA), DGP IgA
(QUANTA Lite Gliadin IgA II ELISA) and DGP
IgG (QUANTA Lite Gliadin IgG II ELISA). All
kits were manufactured by Inova Diagnostics Inc,
USA, and performed according to the manufacturer’s
instructions.
ELISA test results were classiﬁed as negative (<20
units), weak positive (20–30 units), and moderate/
strong positive (>30 units) according the manufac-
turer’s recommendations.
All specimens positive by the tTG IgA ELISA assay
(20 units) were tested by indirect immunoﬂuorescence
(IFA) for the presence of anti-endomysial IgA antibo-
dies (EMA) when suﬃcient serum was available.
Primate distal esophagus tissue substrate (Nova Lite
Endomysial test system, Inova Diagnostics) was used in
the IFA method; detection of EMA at a dilution of 1:5
was interpreted as positive for EMA.
To further assess the performance of the ELISA
assays, additional testing was performed on all speci-
mens for which the tTG IgA ELISA test result was
above 15 units (ﬁve units below the assay’s cutoﬀ)
using the QUANTA-Flash tTG IgA, DGP IgA, and
DGP IgG CIA assays (all assays United States Food
and Drug Administration (FDA) cleared) using the
BIO-FLASH chemiluminescent instrument platform
(Biokit s.a., Barcelona, Spain).
Genotyping
Direct sequencing of the second exon of the HLA-
DQB1 gene and the second and third exons of the
DQA1 gene was performed. DNA samples were dis-
solved in water and aliquoted into 96-well polymerase
chain reaction (PCR) plates or PCR tubes by Tecan
Freedom Evo robotic pipette. The ﬁnal DNA amount
was 28 ng/well. The second exon of HLA-DQB1 and
second and third exons of DQA1 genes were ampliﬁed
and sequenced using the BigDye chemistry and ABI
Prism 3100 (AME Bioscience, Toroed, Norway)
capillary electrophoresis sequencer. All chromatograms
were manually inspected and analyzed using the CLC
Bio Main Workbench package (CLC Bio Inc). Presence
of polymorphisms was conﬁrmed by opposite strand
analysis. Allele calling was performed using the
IMGT/HLA database29,30 sequence alignment tool
and conﬁrmed by manual alignment of allele sequences
from the HLA allele sequence database31 and sequences
obtained by sequencing. DQ 2.5- (HLA-DQA1*05-
DQB1*02 in cis or trans) and/or DQ8- (HLA-
DQA1*03-DQB1*03:02) positive cases were considered
the high-risk genotypes for celiac disease.
Statistics
Descriptive statistics were used to characterize the
study group and the proportion of the positive test
results according to the predeﬁned criteria. Mean
values, range, standard deviation (SD) and 95% conﬁ-
dence intervals (CI) of means were used to describe the
distribution of the measurement results.
Ethical considerations
The project was conducted in accordance with the
Helsinki Declaration; the study protocol was approved
by the Ethics Committee of the Institute of Cardiology,
University of Latvia; and genetic testing has been
approved by the Central Medical Committee of
Ethics in Latvia.
Results
A total of 1444 serum samples were available for the
study. The cohort consisted of 982 (68%) women and
462 men; median age was 57. Approximately 39% (558)
of the samples were collected in Riga, the capital of
Latvia, with the remaining coming from other regions
of the country. The age distribution of study partici-
pants was as follows: age <40 (217 cases, 15.0%); age
40–54 (438 individuals, 30.3%); age 55–69 (542 individ-
uals, 37.6%); >70 years (70 individuals, 17.1%).
Altogether 64 individuals were outside the primary invi-
tation group; seven were younger than 25 and 57 older
than 74.
ELISA serology results
Conventional assay testing results are summarized in
Table 1, while those obtained with CIA assays are
shown in Table 2. Results were combined into several
possible proﬁles and the estimated prevalence calcu-
lated based on either serological test results only or
by combining serological test interpretation with the
presence of DQ2.5 or DQ8 genotype. For the ELISA
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Table 1. The prevalence of celiac test positivity obtained with different ELISA assays with and without considering the DQ typing results
No.
Tests considered to set
a positive result Cutoff
No of
positive
cases
Proportion
of total study
population
in % (95% CI)
No of
DQ2.5- or
DQ8-positive
cases
Proportion
of DQ2.5- or
DQ8-positive
cases out
of serology
positives by
this criteria in %
Proportion
of serology
positive by
this criteria
and DQ2.5- or
DQ8-positive
cases of total
study population
in % (95% CI)
1 Any diagnostic test
positive (tTG IgA,
DGP IgA, DGP IgG);
EMA not considered
>20 U 43 2.98 (2.10–3.86) 18 41.86 1.25 (0.68–1.82)
2 Any diagnostic test
positive (tTG IgA,
DGP IgA, DGP IgG);
EMA not considered
>30 U 20 1.39 (0.79–1.99) 10 50.00 0.69 (0.26–1.12)
3 Any diagnostic test
positive (tTG IgA,
DGP IgA, DGP IgG)
and EMA positive
>20 U 5 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
4 Any diagnostic test
positive (tTG IgA,
DGP IgA, DGP IgG)
and EMA positive
>30 U 5 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
5 Two diagnostic tests
(tTG IgA, DGP IgA,
DGP IgG) positive;
EMA not considered
>20 U 8 0.55 (0.17–0.93) 7 87.50 0.49 (0.13–0.85)
6 Two diagnostic tests
(tTG IgA, DGP IgA,
DGP IgG) positive;
EMA not considered
>30 U 6 0.42 (0.09–0.75) 6 100.00 0.42 (0.09–0.75)
7 All three diagnostic
tests (tTG IgA, DGP
IgA, DGP IgG) posi-
tive; EMA not
considered
>20 U 6 0.42 (0.09–0.75) 6 100.00 0.42 (0.09–0.75)
8 All three diagnostic
tests (tTG IgA, DGP
IgA, DGP IgG) posi-
tive; EMA not
considered
>30 U 4 0.28 (0.01–0.55) 4 100.00 0.28 (0.01–0.55)
9 DGP IgA and DGP IgG
positive (irrespective
of other tests)
>20 U 7 0.49 (0.13–0.85) 7 100.00 0.49 (0.13–0.85)
10 DGP IgA and DGP IgG
positive (irrespective
of other tests)
>30 U 5 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
11 DGP IgA and DGP IgG
positive; tTG IgA
negative (irrespect-
ive of other tests)
>20 U 1 0.07 (0–0.21) 1 100.00 0.07 (0–0.21)
(continued)
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assays, proﬁles were evaluated using both the manufac-
turer’s speciﬁed cutoﬀ of 20 units, as well as a mod-
iﬁed cutoﬀ of >30 units. For the CIA versions of the
assays, the manufacturer’s cutoﬀ of 20 units was used.
The tTG IgA was 20 units in 24 cases (1.66%), 30
units in 11 cases (0.76%), 40 units in seven cases
(0.48%), and 50 units in ﬁve cases (0.35%). The
DGP IgA result was 20 units in 17 cases (1.18%),
30 units in eight cases (0.55%), 40 units in ﬁve cases
(0.35%), and 50 units in four cases (0.28%). The DGP
IgG result was 20 units in 16 cases (1.11%); it
exceeded 30 units in 11 cases (0.76%), 40 units in
seven cases (0.48%), and 50 units in four cases (0.28%).
Six individuals (0.42%) were triple positive at 20 U
for tTG IgA, DGP IgG, and DGP IgA, and four of
these (0.28% of the entire group) had all three markers
>30 U. Among the triple-positive group, the mean tTG
IgA value was 180.7 (range 21.64–269.19; SD 95.67;
95% CI of the mean 80.20–281.10), the mean DGP
IgA was 108.77 (range 21.75–205.97; SD 66.33; 95%
CI 39.16; 178.38), and the mean DGP IgG was 49.02
(range 40.06–58.01; SD 6.98; 95% CI 41.69; 56.34). All
four cases exceeding the 30-unit level for the ELISA
tests were EMA positive. Of the remaining two individ-
uals in whom at least one of the test results ranged
between 20 and 30 units, one was EMA positive and
one was EMA negative.
Eight participants (0.55%) were positive by at least
two markers. Forty-three specimens (2.98%) were posi-
tive by at least one marker with magnitude over 20
units, while 20 cases (1.39%) were positive by at least
one marker with magnitude over 30 units.
CIA serology results
Serology results obtained using CIA were available for
82 cases selected as described in the Methods section.
The selection of the cases allowed us to compare the
result to the group of positive ELISA cases, but also to
the entire study population. Thirteen specimens (0.9%
of the total study group) were positive by one or more
of the CIA assays. Using more stringent criteria of any
two tests positive found seven (0.48%) individuals posi-
tive. Five cases (0.35%) were triple positive. The diﬀer-
ence between the double and triple positive is a result of
two tTG IgA-negative specimens being detected by the
DGP IgG and IgA assays. All triple-positive specimens
were EMA positive. The two specimens that were only
DGP IgG and IgA dual positive were EMA negative as
expected, since they were tTG negative.
Table 1. Continued
No.
Tests considered to set
a positive result Cutoff
No of
positive
cases
Proportion
of total study
population
in % (95% CI)
No of
DQ2.5- or
DQ8-positive
cases
Proportion
of DQ2.5- or
DQ8-positive
cases out
of serology
positives by
this criteria in %
Proportion
of serology
positive by
this criteria
and DQ2.5- or
DQ8-positive
cases of total
study population
in % (95% CI)
12 DGP IgA and DGP IgG
positive; tTG IgA
negative (irrespect-
ive of other tests)
>30 U 1 0.07 (0–0.21) 1 100.00 0.07 (0–0.21)
13 tTG IgA positive (irre-
spective of other
tests)
>20 U 24 1.66 (1.00–2.32) 10 41.67 0.69 (0.26–1.12)
14 tTG IgA positive (irre-
spective of other
tests)
>30 U 11 0.76 (0.31–1.21) 7 63.64 0.49 (0.13–0.85)
15 EMA positive (irre-
spective of other
tests)
1:5 5 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
16 tTG IgA and EMA posi-
tive (irrespective of
other tests)
>20
U/1:5
5 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
ELISA: enzyme-linked immunosorbent assay; tTG IgA: human tissue transglutaminase immunoglobulin A; DGP IgA: deamidated gliadin peptide immuno-
globulin A; DGP IgG: deamidated gliadin peptide immunoglobulin G; EMA: anti-endomysial immunoglobulin A antibodies; CI: confidence interval.
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HLA DQ testing results
All 43 individuals positive for any of the serological
tests along with 280 individuals negative for all sero-
logical tests were available for the analysis. In the ser-
ology-negative group the prevalence of a positive
DQ2.5 genotype was 18.93%, the prevalence of a
DQ8 genotype was 10.36%, but the combination of a
positive DQ2.5 or DQ8 genotype was 28.57%. DQ2.2
was positive in 10.71%, of whom all were DQ2.5 and
DQ8 negative.
In the group of 43 patients in whom at least one
serological test was positive, 37.21% were DQ2.5 posi-
tive, 6.98% were DQ8 positive; 41.86% were positive
for either DQ2.5 or DQ8. A total of 46.5% of the
DQ2.5/DQ8-negative cases in this subgroup were
DQ2.2 positive.
Table 2. The prevalence of celiac test positivity obtained with different chemiluminescent-based immunoassays (CIA) with and without
considering the DQ typing results
No.
Tests considered
to set a positive
result Cutoff
No of CIA
positive
cases
Proportion
of positives
in the CIA
tested
group (%)
Proportion
of positives
from the
entire study
group in
% (95% CI)
No of
DQ2.5 or
DQ8
positives
Proportion
of DQ2.5 or
DQ8 positives
from
CIA-positive
cases (%)
Proportion of
CIA positives and
DQ2.5 or DQ8
positives from the
entire study group
in % (95% CI)
1 Any diagnostic test
positive (tTG IgA,
DGP IgA, DGP IgG);
EMA not considered
>20 U 13 15.85 0.90 (0.41–1.39) 9 69.23 0.62 (0.22–1.02)
2 Any diagnostic test
positive (tTG IgA,
DGP IgA, DGP IgG)
and EMA positive
>30 U 5 6.10 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
3 Two diagnostic tests
(tTG IgA, DGP IgA,
DGP IgG) positive;
EMA not considered
>20 U 7 8.54 0.49 (0.13–0.85) 7 100.00 0.49 (0.13–0.85)
4 All three diagnostic
tests (tTG IgA, DGP
IgA, DGP IgG) posi-
tive; EMA not
considered
>20 U 5 6,10 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65
5 DGP IgA and DGP IgG
positive (irrespective
of other tests)
>20 U 7 8.54 0.49 (0.13–0.85) 7 100.00 0.49 (0.13–0.85)
6 DGP IgA and DGP IgG
positive; tTG IgA
negative (irrespect-
ive of other tests)
>30 U 2 2.44 0.14 (0–0.33) 2 100.00 0.14 (0–0.33)
7 tTG IgA positive (irre-
spective of other
tests)
>20 U 5 6.10 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
8 EMA positive (irre-
spective of other
tests)
1:5 5 6.10 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
9 tTG IgA and EMA posi-
tive (irrespective of
other tests)
>20
U/1:5
5 6.10 0.35 (0.05–0.65) 5 100.00 0.35 (0.05–0.65)
ELISA: enzyme-linked immunosorbent assay; tTG IgA: human tissue transglutaminase immunoglobulin A; DGP IgA: deamidated gliadin
peptide immunoglobulin A; DGP IgG: deamidated gliadin peptide immunoglobulin G; EMA: anti-endomysial immunoglobulin A antibodies; CI: confidence
interval.
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The proportion of the risk genotype (DQ2.5 or DQ8
genotype) in the subgroups of positive serological tests
is presented in Tables 1 and 2.
Discussion
Although celiac disease is considered common, the gen-
eral estimates of 1%–1.5% are based on studies con-
ducted mainly in Northern and Western Europe and
could be an overestimate for other regions of
Europe.23 Even in Western Europe, estimates of the
prevalence of the disease vary, e.g. in Germany the
prevalence in the adult population is estimated to be
approximately 0.3%.2,32
The present study is the ﬁrst on celiac disease epi-
demiology in Latvia, one of the three Baltic countries in
Northeastern Europe where considerable political and
socioeconomic changes have taken place over the last
century. A previous study conducted in schoolchildren
from Estonia, another Baltic country, revealed a 0.34%
prevalence of celiac disease.33,34 In Polish children the
prevalence of conﬁrmed celiac disease is 0.25%, but the
prevalence of positive serology is 0.8%.35
Prevalence ﬁgures in epidemiological studies are sub-
stantially inﬂuenced by the criteria set for diagnosing
celiac disease.2 This was clearly demonstrated in our
study. If the standard cutoﬀ value (20 U) was used,
a positive result was obtained in 2.98% of the popula-
tion, suggesting a high seroprevalence of celiac disease.
However, when more stringent criteria were applied,
the results suggested a lower disease prevalence.
Using a triple-positive criterion (tTG IgA, DGP IgA,
and DGP IgG), positivity ranged between 0.28% and
0.42% depending on the cutoﬀ value used. Adding a
positive EMA test as a requirement for positivity
decreased the prevalence to 0.35%. It should be men-
tioned that our prevalence estimates have been based
on non-invasive testing only; therefore, the prevalence
of biopsy-conﬁrmed celiac disease in this population
could be even lower. Furthermore, since the proportion
of women in our study group was higher than men and
considering the fact that celiac disease is more prevalent
in women,36 this could lead to an additional overesti-
mation of the prevalence in the general population of
the country.
Our study conﬁrmed the usefulness of adding genetic
testing to the conventional serology for establishing the
prevalence ﬁgures of the disease as recently suggested
by Anderson et al.27 When the interpretative criteria
for celiac disease positivity was a positive result of
any ELISA test (cutoﬀ 20 U), the DQ2.5/DQ8 posi-
tivity was only 41.9%, suggesting that a proportion of
the serology positives were unlikely to be true celiacs.
By design, screening algorithms should have high sen-
sitivity to detect all individuals with the speciﬁc disease,
in this case, celiac disease. Presumed false-positive
results (usually low positives) are expected in screening,
and follow-up testing is used to increase speciﬁcity of
the testing. As criteria are made more stringent, the
proportion of positive DQ test results increased; e.g.
when test positivity by two ELISAs is required with a
cutoﬀ of 20 U, the DQ2.5/8 test was positive in 87.5%
cases, but when the cutoﬀ limit was set to >30 U, the
DQ2.5/8 test was positive in 100% of the cases.
Similarly when all three serology tests were positive,
DQ2.5/8 was positive in 100%. Correspondingly, for
the CIA assays, when any of the tTG IgA, DGP IgG,
or DGP IgA tests were positive, 69.2% were DQ2.5 or
DQ8 positive. When any two tests or three tests were
positive, 100% were DQ positive.
Based on the assumption that virtually all celiacs
must have HLA DQ2.5 or DQ8 genes, the combined
results of ELISA, CIA, EMA, and DQ2.5/8 testing sug-
gest at a minimum the prevalence of celiac disease in
Latvia is approximately 0.35% (95% CI: 0.05–0.65%).
This estimate is based on specimens being triple positive
(tTG IgA, DGP IgA, DGP IgG), EMA positive and
possessing HLA DQ2.5 or DQ8. Inclusion of the two
individuals who were DGP IgG and IgA dual positive
and DQ2.5 or DQ8 positive would increase the preva-
lence to 0.49% (95% CI: 0.13–0.85%). We would
speculate that similar prevalence could also be present
in neighboring countries, e.g. other Baltic States or East
European countries with similar socioeconomic
backgrounds.
The accepted standard for the serological screening
for celiac disease is detection of IgA antibodies to tTG.
There are many tTG assays available and overall most
show greater than 93%–95% sensitivity and speciﬁ-
city.37 At least 0.21% of the Caucasian population
has selective IgA deﬁciency and more than 2% of the
population presents with subnormal IgA levels.38
Individuals with IgA deﬁciency have a higher likelihood
of celiac disease than the general population,1 but the
presence of this condition could lead to misdiagnosis if
only IgA-based tests are applied.7 Guidelines com-
monly recommend simultaneous detection of total
serum IgA for ruling out IgA deﬁciency;14 however,
the use of IgG-based tests is an alternative.39
EMA, performed and interpreted by experienced
individuals, remains an extremely speciﬁc test for
celiac disease, but its sensitivity is less than tTG IgA37
and clinically proven patients with the disease can be
missed if this is the only test employed. Moreover,
many laboratories in Europe do not have the EMA
test available; e.g. EMA detection is currently not pro-
vided by any laboratory in Latvia. Therefore, improved
serological or serogenetic approaches are of special
importance to select individuals requiring further diag-
nostic workup, including duodenal biopsies, and also to
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avoid unnecessary investigations. A combination of
two or more assays, especially the addition of DGP
IgA and DGP IgG to tTG tests, was recently suggested
by Schyum and Rumessen.37 Our study conﬁrms the
rationale for such an approach and suggests the add-
ition of the HLA risk-genotype can assist in clarifying
results.
In the present study we used tTG and DGP assays in
the conventional ELISA format as well as a new chemi-
luminescent format. Chemiluminescence allows an
assay with a high signal-to-noise ratio and wide
dynamic range.
The strongest evidence for the presence of celiac
disease is the case where all tests are positive. Using
ELISA, six individuals (0.42%, six of 1444) were
found to be positive for tTG IgA, DGP IgG, and
DGP IgA. All six were also DQ2.5 or DQ8 positive;
ﬁve of these were EMA positive. CIA testing found
ﬁve of the six also positive for all three assays, but
found one specimen tTG IgA negative (this specimen
was very low positive on the ELISA tTG IgA). The
CIA assay picked up two additional specimens
that were tTG IgA negative, but DGP IgG and
IgA positive (and DQ2.5/DQ8 positive). The
ELISA assay also picked up one of these two add-
itional specimens.
The CIA and ELISA tests, in combination with the
HLA DQ 2.5/DQ8 results, detected all ﬁve EMA-posi-
tive cases. For specimens with double or triple positiv-
ity by either CIA or ELISA and the presence of HLA
DQ2.5/DQ8 genotype, the EMA test did not add add-
itional diagnostic value.
Our study has several limitations. By following the
protocol of the study, EMA tests and CIA tests were
not run on the entire study population partly because of
limited serum volume. However, since all specimens
without EMA testing (except for one) were negative
for all celiac serology, it is exceedingly unlikely EMA
testing would have found additional positive specimens.
A major limitation of the current study is the unavail-
ability of duodenal biopsy results, therefore making
deﬁnitive diagnosis of celiac disease impossible.
Follow-up of laboratory-positive individuals with
endoscopic evaluation is being pursued, but is practic-
ally diﬃcult to accomplish.
In conclusion, our study suggests the prevalence of
celiac disease in Latvian adults is lower than in many
neighboring Nordic countries. Furthermore, our
results suggest the rationale for combining several
serological tests, in particular the new CIA versions
of the tTG and DGP assays, may oﬀer higher
performance than conventional ELISAs and that
the addition of HLA DQ2.5/DQ8 genotyping can
help clarify serology results and avoid unnecessary
endoscopies.
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